FindTrial
Sign In

Liovel Combination Tablets special drug use surveillance "Long-term use in patients with type 2 diabetes mellitus"

Liovel Combination Tablets special drug use surveillance "Long-term use in patients with type 2 diabetes mellitus"

Status
Unknown
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-jRCT1080222253
Enrollment
3000
Registered
2013-10-10
Start date
2013-10-10
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus

Interventions

investigational material(s) Generic name etc : Liovel Combination Tablets (alogliptin/pioglitazone) INN of investigational material : Therapeutic category code : 396 Antidiabetic agents Dosage and

Sponsors

TAKEDA PHARMACEUTICAL COMPANY LTD.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with type 2 diabetes mellitus

Exclusion criteria

Exclusion criteria: Patients meeting any of the following criteria will be excluded: 1. Patients with current cardiac failure or a past history of cardiac failure 2. Patients with severe ketosis, diabetic coma or precoma, or type 1 diabetes mellitus 3. Patients with serious hepatic dysfunction 4. Patients with serious renal dysfunction 5. Patients with severe infection, pre- or post-operative patients, or patients with serious traumatic injury 6. Patients with a history of hypersensitivity to any ingredients of Liovel 7. Pregnant or possibly pregnant wome

Design outcomes

Primary

MeasureTime frame
Adverse events (adverse reactions), HbA1c Primary timeframe 12 months Frequency of adverse events (adverse reactions), HbA1c time profile—

Secondary

MeasureTime frame
Fasting blood glucose Secondary timeframe 12 months Changes in fasting blood glucose—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026